Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744978 | 1.00 | NR1H2 (0.39) | NR1H2GRIN2B | |
| SCHEMBL1224727 | 1.00 | NR1H2 (0.39) | NR1H2GRIN2B | |
| SCHEMBL907220 | 0.95 | NR1H2 (0.36) | NR1H2 | |
| SCHEMBL3061976 | 0.86 | KDM4E (0.31) | — | |
| SCHEMBL903879 | 0.81 | NR1H2 (0.65) | NR1H2 | |
| SCHEMBL371676 | 0.81 | NR1H2 (0.65) | NR1H2 | |
| SCHEMBL1225473 | 0.81 | NR1H2 (0.65) | NR1H2 | |
| SCHEMBL17803729 | 0.80 | CHRNB2 (0.36) | NR1H2 | |
| SCHEMBL17803728 | 0.80 | CHRNB2 (0.36) | NR1H2 | |
| SCHEMBL1225484 | 0.80 | KDM4E (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | SYMPHONY EVOLUTION, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-1521747-B1 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | SYMPHONY EVOLUTION INC (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-3329918-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9796704-B2 | Substituted quinazolines as receptor-type kinase inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2409704-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| EP-1673085-A4 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| EP-1673085-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2006-03-30 | — | — | US | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | NR1H2 3554/4885GRIN2B 3040/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | NR1H2 3554/4885GRIN2B 3040/4885 |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | NR1H2 1419/4885GRIN2B 3055/4885 |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | EGFR, ERBB4, ERBB3 | NR1H2 1414/4885GRIN2B 3390/4885 |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | NR1H2 1419/4885GRIN2B 3055/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | NR1H2 3959/4885GRIN2B 2667/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | NR1H2 4016/4885GRIN2B 2736/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | NR1H2 4016/4885GRIN2B 2736/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | NR1H2 4016/4885GRIN2B 2736/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | NR1H2 3959/4885GRIN2B 2667/4885 |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, KDR | NR1H2 3479/4885GRIN2B 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.